RxDoctor Payments Data

John Blumer, MD

Family Medicine · Brunswick, GANPI 1619984150

Payments from drug & device makers

$4,522in general payments, 2019–2025

Across 258 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$589
  • Novo Nordisk$371
  • Amgen$322
  • AbbVie$289
  • Astellas Pharma US Inc$270
  • Sunovion Pharmaceuticals Inc.$240
  • plus $2K from 41 others

What the payments were for

  • Food & beverage$4,39197%
  • Education$1313%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,522 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$133,318
Medicare patients
418
Services billed
1,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide169$168,838
EliquisApixaban161$140,184
MounjaroTirzepatide117$138,109
JanuviaSitagliptin Phosphate194$137,542
LinzessLinaclotide181$136,171
FarxigaDapagliflozin Propanediol131$96,251
JardianceEmpagliflozin61$50,787
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$48,558
RybelsusSemaglutide34$35,592
JanumetSitagliptin Phos/Metformin Hcl26$29,092
TrulicityDulaglutide21$26,105
Janumet XrSitagliptin Phos/Metformin Hcl20$25,255
MyrbetriqMirabegron29$18,083
TradjentaLinagliptin22$14,242
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$13,192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$371$204,431203 claims
MerckJanuvia, Janumet, Janumet Xr$11$191,889240 claims
Lilly USA, LLCMounjaro, Trulicity$130$164,214138 claims
AbbVieLinzess, Synthroid$289$140,863235 claims
PfizerEliquis$200$140,184161 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$102$115,728168 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$55$75,061104 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$589$63,62793 claims
Astellas Pharma US IncMyrbetriq$270$18,08329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Brunswick

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →